Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Emerging technologies for assessing HER2 amplification Penault-Llorca F; Bilous M; Dowsett M; Hanna W; Osamura RY; Ruschoff J; van de Vijver MAm J Clin Pathol 2009[Oct]; 132 (4): 539-48Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated for determining the HER2 status of breast tumors in the routine diagnostic setting: immunohistochemical analysis and fluorescence in situ hybridization (FISH). Recently, bright-field in situ hybridization techniques such as chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which combine features of immunohistochemical analysis and FISH, have been introduced for the determination of HER2 status. These new techniques use a peroxidase enzyme-labeled probe with chromogenic detection, instead of a fluorescent-labeled probe, allowing results to be visualized by standard bright-field microscopy. Thus, the histologic features and HER2 status of a specimen can be evaluated in parallel. Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis.|*Gene Amplification[MESH]|Algorithms[MESH]|Antibodies, Monoclonal[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Breast Neoplasms/genetics[MESH]|Chromogenic Compounds[MESH]|Genes, erbB-2/*genetics[MESH]|Humans[MESH]|Immunohistochemistry/methods[MESH]|In Situ Hybridization, Fluorescence/methods[MESH]|In Situ Hybridization/methods[MESH]|Observer Variation[MESH]|Receptor, ErbB-2/biosynthesis/genetics[MESH]|Silver[MESH]|Trastuzumab[MESH] |